-
Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study
11 Jul 2025 11:55 GMT
… Bradner, executive vice president of research and development at Amgen, said … announced later this year.
Amgen gained access to bemarituzumab in … , chairman and chief executive officer at Amgen, said at the … Five Prime team to Amgen and working with them …
-
New Amgen data highlights promise in gastric cancer
09 Jul 2025 02:24 GMT
… top-line results from Amgen’s Phase III FORTITUDE … Bradner, Executive Vice President of Research and Development at Amgen.
Gastric … biologic bemarituzumab, according to Amgen.
Following their announcement of … this top-line data, Amgen plans to share detailed …
-
Crohn's Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Anssen, Redhill Biopharma, Amgen, Pfizer, Prometheus Biosciences, Agomab Therape
09 Jul 2025 01:44 GMT
… such as Anssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics … Content
1. Report Introduction
2. Executive Summary
3. Crohn's …
-
US close: Stocks flat as Trump signals no more tariff extensions
09 Jul 2025 00:10 GMT
… 7% on Monday following chief executive Elon Musk's announcement … ) $273.79 1.43%
Amgen Inc. (AMGN) $297.00 1.38%
Unitedhealth … . (NEE) $72.46 -3.06%
Nasdaq 100 - Risers
Intel Corp … . (SWKS) $77.94 2.30%
Nasdaq 100 - Fallers
Seagate Technology …
-
EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy
11 Jul 2025 11:55 GMT
… approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab … of osteoclasts.
Biocon Biologics’ chief executive officer and managing director, Shreehas …
-
Paroxysmal Nocturnal Hemoglobinuria Treatment Market Set For Robust Growth Through 2034, Driven By Advancing Clinical Development Pipeline Delveinsight
11 Jul 2025 03:21 GMT
… , AKARI Therapeutics, Alexion, Novartis, Amgen, BioCryst, MorphoSys, Ra Pharmaceuticals, … 1. Key Insights
2. Executive Summary of Paroxysmal Nocturnal … , Alexion Pharmaceuticals, Novartis Pharmaceuticals, Amgen, BioCryst Pharmaceuticals, MorphoSys, Ra …
-
Vitiligo Treatment Innovation Accelerates With JAK Inhibitors And Novel Immunotherapies Delveinsight
11 Jul 2025 03:22 GMT
… Incyte Corporation, TWi Biotechnology, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio … candidates like AMG-714 (Amgen), an anti-IL-15 … of stable ones. Additionally, Amgen's AMG 714 , … Contents
1. Introduction
2. Executive Summary
3. Vitiligo: Overview …
-
Crohn's Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight
10 Jul 2025 03:19 GMT
… as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, … Companies
Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, … Companies- Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, … Crohn's Disease Executive Summary
Crohn's …
-
Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight
10 Jul 2025 01:16 GMT
… the 7MM in 2034
4
Executive Summary
5
Key Events
6 … -alpha inhibitors companies, including AbbVie, Amgen, Johnson & Johnson (through Janssen …
-
Ghana records approximately 24,000 cancer cases annually – Gunu
09 Jul 2025 22:51 GMT
… Nurses in Cancer (ISNCC) and Amgen, Funder, a Biotechnology and pharmaceutical … initiative,” Sean Lybrand, Executive Director, Access to Healthcare, Amgen Inc. said.
Togbe …
About
© 1995-2025